Commentary
Video
4-Year Data for First-Line Nivolumab Plus Chemo in Advanced Gastric/GEJ Cancer
Author(s):
Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.
EP: 1.Immunotherapy's Effect on the Upper GI Cancer Treatment Paradigm
Now Viewing
EP: 2.4-Year Data for First-Line Nivolumab Plus Chemo in Advanced Gastric/GEJ Cancer
EP: 3.A Q-TWiST Analysis from the CheckMate 649 Trial of Nivolumab/Chemo in Advanced Gastric/GEJ Cancer
EP: 4.Long-Term Data for Frontline Nivolumab Plus Chemo or Ipilimumab in Advanced ESCC
EP: 5.Factors for Selecting Nivolumab Plus Chemo or Nivolumab Plus Ipilimumab in Advanced ESCC
EP: 6.Immunotherapy's Role in Improving Durability of Outcomes in Advanced Upper GI Cancers
Related Videos
Related Content
